文献速递呼吸衰竭与机械通气心脑血管急症重症综合管理与镇静镇痛

气道正压与睡眠呼吸暂停成人患者心血管事件及死亡的相关性:系统评价与Meta分析

Association of Positive Airway Pressure With Cardiovascular Events and Death in Adults With Sleep Apnea: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA · 2017-01-01
一句话结论对于睡眠呼吸暂停患者,与不治疗或假治疗相比,气道正压治疗与心血管结局或死亡风险降低无关,这些发现不支持以预防这些结局为目标使用气道正压治疗。

该系统评价与Meta分析检索了MEDLINE、EMBASE和Cochrane图书馆自建库至2017年3月的随机临床试验,纳入10项试验(9项CPAP,1项ASV),共7266例睡眠呼吸暂停患者(平均年龄60.9岁,范围51.5至71.1岁;5847例[80.5%]男性;平均[SD]体重指数30.0[5.2])。记录到356例主要不良心血管事件和613例死亡。气道正压治疗与主要不良心血管事件(RR,0.77[95%CI,0.53至1.13];P=.19;RD,-0.01[95%CI,-0.03至0.01];P=.23)、心血管死亡(RR,1.15[95%CI,0.88至1.50];P=.30;RD -0.00[95%CI,-0.02至0.02];P=.87)或全因死亡(RR,1.13[95%CI,0.99至1.29];P=.08;RD,0.00[95%CI,-0.01至0.01];P=.51)均无显著关联。急性冠脉综合征、卒中和心力衰竭的结果相同。CPAP与ASV之间无证据表明关联不同(所有P值同质性>.24),Meta回归未发现气道正压与不同呼吸暂停严重程度、随访时长或气道正压依从性水平下的结局存在关联(所有P值>.13)。

要点

  • 在10项试验共7266例睡眠呼吸暂停患者中,气道正压治疗与主要不良心血管事件无显著关联(RR,0.77[95%CI,0.53至1.13];P=.19)。
  • 气道正压治疗与心血管死亡无显著关联(RR,1.15[95%CI,0.88至1.50];P=.30),与全因死亡亦无显著关联(RR,1.13[95%CI,0.99至1.29];P=.08)。
  • 急性冠脉综合征、卒中和心力衰竭的结果与主要结局一致。
  • CPAP与ASV之间无证据表明关联不同(所有P值同质性>.24)。
  • Meta回归未发现气道正压与不同呼吸暂停严重程度、随访时长或气道正压依从性水平下的结局存在关联(所有P值>.13)。

适用人群与场景

  • 纳入随机临床试验的睡眠呼吸暂停(阻塞性和中枢性)成人患者,共7266例,平均年龄60.9岁(范围51.5至71.1岁),5847例(80.5%)为男性,平均(SD)体重指数30.0(5.2)。

研究设计与关键结果

  • 研究类型为系统评价与Meta分析,纳入10项随机临床试验(9项CPAP,1项ASV),共7266例睡眠呼吸暂停患者。
  • 主要结局为主要不良心血管事件复合终点(急性冠脉综合征事件、卒中或血管性死亡的复合),记录到356例主要不良心血管事件和613例死亡。
  • 气道正压治疗与主要不良心血管事件无显著关联(RR,0.77[95%CI,0.53至1.13];P=.19;RD,-0.01[95%CI,-0.03至0.01];P=.23)。
  • 气道正压治疗与心血管死亡无显著关联(RR,1.15[95%CI,0.88至1.50];P=.30;RD -0.00[95%CI,-0.02至0.02];P=.87)。
  • 气道正压治疗与全因死亡无显著关联(RR,1.13[95%CI,0.99至1.29];P=.08;RD,0.00[95%CI,-0.01至0.01];P=.51)。
  • 急性冠脉综合征、卒中和心力衰竭的结果与主要结局一致。
  • CPAP与ASV之间无证据表明关联不同(所有P值同质性>.24),Meta回归未发现气道正压与不同呼吸暂停严重程度、随访时长或气道正压依从性水平下的结局存在关联(所有P值>.13)。

证据类型、等级与局限

  • 证据类型为系统评价与Meta分析,纳入10项随机临床试验(9项CPAP,1项ASV)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于睡眠呼吸暂停成人患者,与不治疗或假治疗相比,气道正压治疗未显示与心血管结局或死亡风险降低相关,这些发现不支持以预防这些结局为目标使用气道正压治疗。
  • 作者指出,气道正压治疗睡眠呼吸暂停还有其他获益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Sleep apnea (obstructive and central) is associated with adverse cardiovascular risk factors and increased risks of cardiovascular disease. Positive airway pressure (PAP) provides symptomatic relief, whether delivered continuously (CPAP) or as adaptive servo-ventilation (ASV), but the associations with cardiovascular outcomes and death are unclear.

OBJECTIVE: To assess the association of PAP vs control with cardiovascular events and death in patients with sleep apnea.

DATA SOURCES AND STUDY SELECTION: MEDLINE, EMBASE, and the Cochrane Library were systematically searched from inception date to March 2017 for randomized clinical trials that included reporting of major adverse cardiovascular events or deaths.

DATA EXTRACTION AND SYNTHESIS: Two authors independently extracted data using standardized forms. Summary relative risks (RRs), risk differences (RDs) and 95% CIs were obtained using random-effects meta-analysis.

MAIN OUTCOMES AND MEASURES: The main outcomes were a composite of acute coronary syndrome (ACS) events, stroke, or vascular death (major adverse cardiovascular events); cause-specific vascular events; and death.

RESULTS: The analyses included data from 10 trials (9 CPAP; 1 ASV) of patients with sleep apnea (N = 7266; mean age, 60.9 [range, 51.5 to 71.1] years; 5847 [80.5%] men; mean [SD] body mass index, 30.0 [5.2]. Among 356 major adverse cardiovascular events and 613 deaths recorded, there was no significant association of PAP with major adverse cardiovascular events (RR, 0.77 [95% CI, 0.53 to 1.13]; P = .19 and RD, -0.01 [95% CI, -0.03 to 0.01]; P = .23), cardiovascular death (RR, 1.15 [95% CI, 0.88 to 1.50]; P = .30 and RD -0.00 [95% CI, -0.02 to 0.02]; P = .87), or all-cause death (RR, 1.13 [95% CI, 0.99 to 1.29]; P = .08 and RD, 0.00 [95% CI, -0.01 to 0.01]; P = .51). The same was true for ACS, stroke, and heart failure. There was no evidence of different associations for CPAP vs ASV (all P value homogeneity >.24), and meta-regressions identified no associations of PAP with outcomes for different levels of apnea severity, follow-up duration, or adherence to PAP (all P values > .13).

CONCLUSIONS AND RELEVANCE: The use of PAP, compared with no treatment or sham, was not associated with reduced risks of cardiovascular outcomes or death for patients with sleep apnea. Although there are other benefits of treatment with PAP for sleep apnea, these findings do not support treatment with PAP with a goal of prevention of these outcomes.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Yu J, Zhou Z, McEvoy RD, et al. Association of Positive Airway Pressure With Cardiovascular Events and Death in Adults With Sleep Apnea: A Systematic Review and Meta-analysis. JAMA. 2017. PMID: 28697252. doi:10.1001/jama.2017.7967

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。